Prothena Corp Public (PRTA) Shares Outstanding (Weighted Average) (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Shares Outstanding (Weighted Average) of $53.7 million in Q1 2026, little changed quarter-over-quarter from $53.8 million in Q4 2025, and little changed on a YoY basis from $53.8 million in Q1 2025.
Prothena Corp Public (PRTA) Shares Outstanding (Weighted Average) (2012 - 2026) Analysis & Trends
Prothena Corp Public's Shares Outstanding (Weighted Average) history runs 15 years deep, the most recent figure standing at $53.7 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) changed 0.22% year-over-year to $53.7 million; the TTM figure through Mar 2026 stood at $53.7 million (changed 0.22% YoY), while the FY2025 annual figure was $53.8 million, changed 0.11% from the prior year.
- Shares Outstanding (Weighted Average) was $53.7 million for Q1 2026 at Prothena Corp Public, roughly flat from $53.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $53.8 million in Q3 2025 to a low of $46.7 million in Q1 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $52.0 million across 5 years, with a median of $53.7 million in 2026.
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Weighted Average) increased 16.03% in 2022, then dropped 0.22% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $47.4 million in 2022, then rose by 12.34% to $53.2 million in 2023, then gained by 1.04% to $53.8 million in 2024, then grew by 0.11% to $53.8 million in 2025, then declined by 0.22% to $53.7 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $53.7 million (Q1 2026), $53.8 million (Q4 2025), and $53.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 53.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.71 Mn |
| Dec 31, 2025 | 53.83 Mn |
| Sep 30, 2025 | 53.83 Mn |
| Jun 30, 2025 | 53.83 Mn |
| Mar 31, 2025 | 53.83 Mn |
| Dec 31, 2024 | 53.77 Mn |
| Sep 30, 2024 | 53.76 Mn |
| Jun 30, 2024 | 53.74 Mn |
| Mar 31, 2024 | 53.71 Mn |
| Dec 31, 2023 | 53.22 Mn |
| Sep 30, 2023 | 53.06 Mn |
| Jun 30, 2023 | 53.12 Mn |
| Mar 31, 2023 | 52.50 Mn |
| Dec 31, 2022 | 47.37 Mn |
| Sep 30, 2022 | 46.99 Mn |
| Jun 30, 2022 | 46.76 Mn |
| Mar 31, 2022 | 46.70 Mn |
| Dec 31, 2021 | 44.23 Mn |
| Sep 30, 2021 | 45.63 Mn |
| Jun 30, 2021 | 42.30 Mn |